Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose weekly pegvisomant added to long-acting somatostatin analogs in biochemically controlled acromegaly
NL-OMON24622Phase 3Completed
- Sponsor
- Erasmus MC
- Start
- Aug 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acromegaly comparing Pegvisomant add-on with Placebo add-on (2 arms). Primary endpoint: Change in AcroQoL physical score. Started Aug 2013; status: completed.
02
Drugs
pegvisomant
03
Conditions
acromegaly
Beyond the preview
Go deeper on NL-OMON24622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24622.